Holen Sie sich die Stockscreener-App
0.0924
1.70%
-0.0016
Schlusskurs vom Vortag:
$0.094
Offen:
$0.096
24-Stunden-Volumen:
1.34M
Relative Volume:
0.44
Marktkapitalisierung:
$6.12M
Einnahmen:
$1.47M
Nettoeinkommen (Verlust:
$-97.61M
KGV:
-0.062
EPS:
-1.49
Netto-Cashflow:
$-80.90M
1W Leistung:
-18.09%
1M Leistung:
-0.65%
6M Leistung:
-51.11%
1J Leistung:
-73.01%
1-Tages-Spanne:
$0.0844
$0.096
1-Wochen-Bereich:
$0.0844
$0.14
52-Wochen-Spanne:
$0.082
$0.3468
Lyra Therapeutics Inc Stock (LYRA) Company Profile
Firmenname
Lyra Therapeutics Inc
Sektor
Branche
Telefon
617-373-4600
Adresse
480 ARSENAL WAY, WATERTOWN, MA
Vergleichen Sie LYRA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LYRA
Lyra Therapeutics Inc
|
0.0924 | 7.47M | 1.47M | -97.61M | -80.90M | -1.49 |
|
ONC
Beigene Ltd Adr
|
238.76 | 24.41B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
434.03 | 111.55B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.2548 | 42.47M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
596.85 | 63.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
72.69 | 5.92B | 0 | -153.72M | -103.81M | -2.00 |
Lyra Therapeutics Inc Stock (LYRA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-05-07 | Herabstufung | BofA Securities | Buy → Underperform |
| 2024-05-07 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2024-05-07 | Herabstufung | Jefferies | Buy → Hold |
| 2024-05-06 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2023-10-06 | Fortgesetzt | BTIG Research | Buy |
| 2023-08-31 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-05-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-05-26 | Eingeleitet | BTIG Research | Buy |
| 2020-05-26 | Eingeleitet | BofA/Merrill | Buy |
| 2020-05-26 | Eingeleitet | Jefferies | Buy |
| 2020-05-26 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Lyra Therapeutics Inc Aktie (LYRA) Neueste Nachrichten
Petri Dish: Thermo Fisher’s new partner; Waters buys California company - The Business Journals
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
US Stocks Likely To Open Lower After S&P 500's Six-Day Streak: 'Quick Recoveries Tend To See Stocks Rally More Over The Next 3-12 Months,' Says ExpertASP Isotopes (NASDAQ:ASPI) - Benzinga
Why Pegasystems Shares Are Trading Higher By Over 6%; Here Are 20 Stocks Moving Premarket - Benzinga
Lyra Therapeutics Announces Reverse Stock Split Decision - TipRanks
Lyra Therapeutics Reports Q1 2025 Financial Results - TipRanks
Lyra Therapeutics, Inc. (LYRA) Reports Q1 Loss, Lags Revenue Estimates - MSN
JPMorgan Chase & Co. Has $32,000 Stake in Lyra Therapeutics, Inc. (NASDAQ:LYRA) - Defense World
JPMorgan Chase & Co. Has $40,000 Stake in Tevogen Bio Holdings Inc. (NASDAQ:TVGN) - Defense World
Lyra Therapeutics to Present 52-Week Extension Stage Results for Enlighten 1 Phase 3 Study for Lyr-210 for the Treatment of Chronic Rhinosinusitis At Cosm 2025 - marketscreener.com
C4 Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights - The Manila Times
Lyra Therapeutics Reports Positive Safety and Efficacy Results for LYR-210 in Phase 3 Extension Study for Chronic Rhinosinusitis - Nasdaq
Lyra Therapeutics to Present 52-week Extension Stage - GlobeNewswire
Lyra Therapeutics Inc expected to post a loss of 14 cents a shareEarnings Preview - TradingView
Lyra Therapeutics to Present 52-week Extension Stage Results for ENLIGHTEN 1 Phase 3 Study for LYR-210 for the Treatment of Chronic Rhinosinusitis at COSM 2025 - GlobeNewswire Inc.
Lyra Therapeutics, Inc. (NASDAQ:LYRA) Receives $1.25 Consensus Target Price from Analysts - Defense World
Lyra Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update - The Manila Times
JPMorgan Chase & Co. Boosts Stock Holdings in Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World
Geode Capital Management LLC Has $183,000 Stock Position in Lyra Therapeutics, Inc. (NASDAQ:LYRA) - Defense World
Ascendiant Capital Markets Predicts VMAR Q1 Earnings - Defense World
Lyra Therapeutics Inc (LYRA) expanding its growth trajectory ahead - Sete News
Financial Fitness Check: Examining B. Riley Financial Inc (RILY)’s Key Ratios - DWinneX
Rhinitis Pipeline 2025: Groundbreaking Clinical Advancements - openPR.com
Keeping an Eye on Lyra Therapeutics Inc (LYRA) After Insider Trading Activity - knoxdaily.com
Lyra Therapeutics Inc (LYRA) Stock: 52-Week Performance Showcases Highs, Lows, and Trading Volume - investchronicle.com
What was Lyra Therapeutics Inc (LYRA)’s performance in the last session? - uspostnews.com
Recent Insider Activity Could Benefit Schrodinger Inc (SDGR) - knoxdaily.com
Layoff Tracker: Ono Cuts 83 Employees in Massachusetts - BioSpace
Lyra Therapeutics (LYRA) to Release Quarterly Earnings on Tuesday - The AM Reporter
Lyra Therapeutics (LYRA) Expected to Announce Quarterly Earnings on Tuesday - American Banking and Market News
iCoreConnect Inc [ICCT] Shares Fall Approximately -87.86% Over the Year - knoxdaily.com
Lyra Therapeutics Inc [LYRA] Shares Rise 7.02 % on Thursday - knoxdaily.com
QBTS Stock Sees Surge of Approximately 14.13% in Last Five Days - knoxdaily.com
Deckers Outdoor Corp [DECK] Records 200-Day SMA of $160.33 - knoxdaily.com
Shopify Inc [SHOP] Records 50-Day SMA of $99.94 - knoxdaily.com
Analysts Say Lyra Therapeutics Inc (NASDAQ:LYRA) Can Really Get To 0.5 In 12 Months - Marketing Sentinel
An Analysis of Lyra Therapeutics Inc (LYRA)’s Potential Price Growth - knoxdaily.com
Take off with Lyra Therapeutics Inc (LYRA): Get ready for trading - Sete News
Is Lyra Therapeutics Inc (LYRA) worth investing in despite its undervalued state? - uspostnews.com
Brokerages Set Lyra Therapeutics, Inc. (NASDAQ:LYRA) Target Price at $1.25 - Defense World
Lyra Therapeutics stock hits 52-week low at $0.1 By Investing.com - Investing.com Australia
Lyra Therapeutics stock hits 52-week low at $0.1 - Investing.com
TCBI Stock Sees Decline of Approximately -2.19% in Last Five Days - knoxdaily.com
Technical analysis of Lyra Therapeutics Inc (LYRA) stock chart patterns - uspostnews.com
Vivos Therapeutics, Inc. (VVOS) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance
Lyra Therapeutics stock hits 52-week low at $0.14 amid sharp decline By Investing.com - Investing.com South Africa
Lyra Therapeutics stock hits 52-week low at $0.14 amid sharp decline - Investing.com Australia
PTCT Stock Sees Decline of Approximately -2.93% in Last Five Days - knoxdaily.com
Lyra Therapeutics Inc (LYRA) deserves deeper analysis - uspostnews.com
A Closer Look at Lyra Therapeutics Inc (LYRA) Stock Gains - investchronicle.com
Lyra Therapeutics stock plunges to 52-week low of $0.16 By Investing.com - Investing.com Australia
Finanzdaten der Lyra Therapeutics Inc-Aktie (LYRA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.60%
6.92%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):